biobucks

Halloween deal shake hands zombie
Biotech

AbbVie pays $65M for options on EvolveImmune's T-cell engagers

Days after inking a $1.4 billion buyout, AbbVie has put up the same in biobucks to secure options on multispecific T-cell engagers.
Nick Paul Taylor Oct 31, 2024 10:00am
Bottle of glue

Biogen buys in to molecular glues with deal worth up to $1.45B

Oct 30, 2024 10:50am
Audience at rock concert

Novartis inks $150M deal for autoimmune molecular glue

Oct 28, 2024 7:00am
An artists concept of gene editing A DNA strand appears in blue with edited regions in red

Editas prioritizes in vivo therapies, seeks reni-cel partner

Oct 22, 2024 9:39am
Merck Co headquarters

Merck signs $1.9B deal to explore fibroblast therapies

Oct 8, 2024 8:55am
IPO scout look ahead telescope up forward

Lilly, Haya ink $1B biobuck obesity pact to search dark genome

Sep 4, 2024 8:00am